Emerging studies suggest Retatrutide , a dual activator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , appears to represent a promising development for obesity treatment. Preliminary patient tests have indicated substantial losses in visceral mass , possibly surpassing here current weight-loss therapies . Nevertheless , mor